JP2019520361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520361A5 JP2019520361A5 JP2018567665A JP2018567665A JP2019520361A5 JP 2019520361 A5 JP2019520361 A5 JP 2019520361A5 JP 2018567665 A JP2018567665 A JP 2018567665A JP 2018567665 A JP2018567665 A JP 2018567665A JP 2019520361 A5 JP2019520361 A5 JP 2019520361A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- intranasal
- naltrexone
- intravail
- dodecyl maltoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 57
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 30
- 229960003086 naltrexone Drugs 0.000 claims description 30
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 208000007848 Alcoholism Diseases 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 208000025746 alcohol use disease Diseases 0.000 claims description 4
- CAHQGWAXKLQREW-UHFFFAOYSA-N Benzal chloride Chemical compound ClC(Cl)C1=CC=CC=C1 CAHQGWAXKLQREW-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 229940037001 sodium edetate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 36
- 229960000686 benzalkonium chloride Drugs 0.000 description 15
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- -1 alkyl saccharide Chemical class 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 229920001661 Chitosan Polymers 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 108010007979 Glycocholic Acid Proteins 0.000 description 3
- 229920002884 Laureth 4 Polymers 0.000 description 3
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 3
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 3
- 229940099347 glycocholic acid Drugs 0.000 description 3
- 229940062711 laureth-9 Drugs 0.000 description 3
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022058125A JP7492548B2 (ja) | 2016-06-24 | 2022-03-31 | アルコール使用障害の処置のための組成物、装置、及び、方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354465P | 2016-06-24 | 2016-06-24 | |
| US62/354,465 | 2016-06-24 | ||
| US201662419736P | 2016-11-09 | 2016-11-09 | |
| US62/419,736 | 2016-11-09 | ||
| PCT/US2017/039300 WO2017223566A1 (en) | 2016-06-24 | 2017-06-26 | Compositions, devices, and methods for the treatment of alcohol use disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022058125A Division JP7492548B2 (ja) | 2016-06-24 | 2022-03-31 | アルコール使用障害の処置のための組成物、装置、及び、方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520361A JP2019520361A (ja) | 2019-07-18 |
| JP2019520361A5 true JP2019520361A5 (https=) | 2020-07-27 |
Family
ID=60784803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567665A Pending JP2019520361A (ja) | 2016-06-24 | 2017-06-26 | アルコール使用障害の処置のための組成物、装置、及び、方法 |
| JP2022058125A Active JP7492548B2 (ja) | 2016-06-24 | 2022-03-31 | アルコール使用障害の処置のための組成物、装置、及び、方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022058125A Active JP7492548B2 (ja) | 2016-06-24 | 2022-03-31 | アルコール使用障害の処置のための組成物、装置、及び、方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190209464A1 (https=) |
| EP (1) | EP3474842A4 (https=) |
| JP (2) | JP2019520361A (https=) |
| KR (2) | KR102634829B1 (https=) |
| CN (1) | CN109789122A (https=) |
| AU (2) | AU2017281941A1 (https=) |
| CA (1) | CA3028731A1 (https=) |
| MX (2) | MX2018015985A (https=) |
| NZ (1) | NZ750067A (https=) |
| PH (1) | PH12018502738A1 (https=) |
| RU (2) | RU2767062C2 (https=) |
| SG (2) | SG11201811580SA (https=) |
| WO (1) | WO2017223566A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102634829B1 (ko) * | 2016-06-24 | 2024-02-07 | 오피언트 파마슈티컬스, 인코퍼레이티드 | 알코올 사용 장애의 치료용 조성물, 장치 및 방법 |
| US11069446B1 (en) * | 2016-09-28 | 2021-07-20 | Cerner Innovation, Inc. | Predicting addiction relapse and decision support tool |
| CA3043028A1 (en) * | 2016-11-09 | 2018-05-17 | Opiant Pharmaceuticals, Inc. | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions |
| IL312012A (en) * | 2016-11-18 | 2024-06-01 | Opiant Pharmaceuticals Inc | Compositions and methods for the treatment of opioid overdose |
| WO2019157099A1 (en) | 2018-02-06 | 2019-08-15 | Aegis Therapeutics, Llc | Intranasal epinephrine formulations and methods for the treatment of disease |
| WO2019222408A1 (en) * | 2018-05-17 | 2019-11-21 | Aegis Therapeutics Llc | Formulations and methods for the prevention of opioid overdose |
| AU2019403368A1 (en) * | 2018-12-20 | 2021-07-29 | Aegis Therapeutics, Llc | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
| AU2020245535B2 (en) | 2019-03-26 | 2022-06-30 | Pinova Therapeutics Inc. | Devices and methods for delivering pharmaceutical compositions |
| CN113784703A (zh) * | 2019-05-16 | 2021-12-10 | 株式会社新日本科学 | 经鼻施予用粉末制剂及其制造方法 |
| US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| CA3166250A1 (en) | 2020-02-05 | 2021-08-12 | Gregory G. Plucinski | Drug products for intranasal administration and uses thereof |
| US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
| MX2024001659A (es) | 2021-08-04 | 2024-06-26 | Indivior Inc | Composiciones y métodos para el tratamiento de la sobredosis por opioides. |
| US20250134883A1 (en) * | 2022-01-26 | 2025-05-01 | Tulex Pharmaceuticals Inc. | Novel compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4882335A (en) * | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| US5069895A (en) * | 1989-11-09 | 1991-12-03 | Diamond Ivan F | Methods for the treatment of alcohol intoxication and dependence |
| EP0444778A1 (en) * | 1990-02-14 | 1991-09-04 | Alcon Laboratories, Inc. | Use of alkyl saccharides to enhance the penetration of drugs |
| EP1423116A1 (en) * | 2001-08-14 | 2004-06-02 | Biotie Therapies Corp. | Method of treating alcoholism or alcohol abuse |
| US9895444B2 (en) * | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US20070212307A1 (en) * | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
| US20100076006A1 (en) * | 2007-01-31 | 2010-03-25 | University Of Virginia Patent Foundation | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders |
| WO2009029308A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| JP5437236B2 (ja) * | 2008-04-16 | 2014-03-12 | 一般財団法人化学及血清療法研究所 | トロンビン固定化生体吸収性シート製剤の製造方法 |
| PE20131137A1 (es) * | 2010-10-29 | 2013-10-03 | Troikaa Pharmaceuticals Ltd | Composiciones nasales de vitamina b12 |
| MY194947A (en) * | 2011-05-13 | 2022-12-27 | Euro Celtique Sa | Intranasal pharmaceutical dosage forms comprising naloxone |
| US10485798B2 (en) * | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| US20140171458A1 (en) * | 2012-12-13 | 2014-06-19 | 3B Pharmaceuticals, Inc. | Intranasal naltrexone |
| DE202013105715U1 (de) * | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
| WO2015095389A1 (en) * | 2013-12-18 | 2015-06-25 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US9480644B2 (en) * | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| KR102634829B1 (ko) * | 2016-06-24 | 2024-02-07 | 오피언트 파마슈티컬스, 인코퍼레이티드 | 알코올 사용 장애의 치료용 조성물, 장치 및 방법 |
-
2017
- 2017-06-26 KR KR1020227034876A patent/KR102634829B1/ko active Active
- 2017-06-26 RU RU2019101810A patent/RU2767062C2/ru active
- 2017-06-26 CA CA3028731A patent/CA3028731A1/en active Pending
- 2017-06-26 EP EP17816377.0A patent/EP3474842A4/en not_active Withdrawn
- 2017-06-26 JP JP2018567665A patent/JP2019520361A/ja active Pending
- 2017-06-26 WO PCT/US2017/039300 patent/WO2017223566A1/en not_active Ceased
- 2017-06-26 SG SG11201811580SA patent/SG11201811580SA/en unknown
- 2017-06-26 RU RU2022103366A patent/RU2022103366A/ru unknown
- 2017-06-26 NZ NZ750067A patent/NZ750067A/en unknown
- 2017-06-26 MX MX2018015985A patent/MX2018015985A/es unknown
- 2017-06-26 SG SG10202013034QA patent/SG10202013034QA/en unknown
- 2017-06-26 AU AU2017281941A patent/AU2017281941A1/en not_active Abandoned
- 2017-06-26 US US16/311,944 patent/US20190209464A1/en not_active Abandoned
- 2017-06-26 KR KR1020197001264A patent/KR102453781B1/ko active Active
- 2017-06-26 CN CN201780044057.3A patent/CN109789122A/zh active Pending
-
2018
- 2018-12-18 MX MX2022013671A patent/MX2022013671A/es unknown
- 2018-12-21 PH PH12018502738A patent/PH12018502738A1/en unknown
-
2022
- 2022-03-31 JP JP2022058125A patent/JP7492548B2/ja active Active
-
2023
- 2023-04-20 AU AU2023202420A patent/AU2023202420A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520361A5 (https=) | ||
| RU2019101810A (ru) | Составы, устройства и способы для лечения алкогольной зависимости | |
| JP2023133494A (ja) | ステロイドの抗痙攣活性 | |
| JP2022088592A5 (https=) | ||
| RU2607892C2 (ru) | Композиции на основе ксилита, препятствующие отделению слизи, а также смежные способы и композиции | |
| JP5683719B2 (ja) | ベポタスチン組成物 | |
| JP4500045B2 (ja) | 感冒の治療のための組成物 | |
| US9844580B2 (en) | Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis | |
| CN102159244A (zh) | 包含减充血剂和皮质类固醇的鼻内组合物 | |
| CN105792828A (zh) | 使用莫米松和奥洛他定的组合治疗过敏性鼻炎 | |
| US9023815B2 (en) | Method for treating rhinitis and sinusitis by rhamnolipids | |
| CN102905689A (zh) | 包含低剂量纳曲酮的液体鼻喷雾 | |
| CA2698135C (en) | Osmolytes for treating allergic or viral respiratory diseases | |
| JP2022535920A5 (https=) | ||
| US20200000751A1 (en) | Carboxylic acids for treating/preventing nasal congestion | |
| JP2014515360A (ja) | フルチカゾンを含む鼻用医薬製剤 | |
| WO2020031148A1 (en) | Pharmaceutical composition, medicinal product and method of treatment of bronchopulmonary obstructive diseases | |
| ES2994461T3 (en) | Method of diagnosis of adrenal insufficiency | |
| JP6153193B2 (ja) | アレルギー性疾患の予防または治療のための医薬組成物 | |
| RU2021121189A (ru) | Композиции, устройства и способы для лечения расстройств передозировки и связанных с вознаграждением | |
| CN111902138A (zh) | 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗 | |
| WO2019090405A1 (pt) | Medicamento de ciclesonida para cura e prevenção da gripe causada pelo vírus influenza | |
| JP2005281227A (ja) | インフルエンザウイルス感染症の治療および予防薬 |